Live tape
Top 8, mentions 7d10,776GOOGL2,063 mentions▲ +0.04SNDK1,523 mentions▲ +0.11SPCX1,494 mentions▲ +0.08NBIS1,420 mentions▲ +0.09HTZ1,232 mentions▲ +0.10NVDA1,189 mentions▲ +0.08META1,016 mentions▲ +0.03MSFT839 mentions▲ +0.06

Equity · Healthcare

PRAX

Praxis Precision Medicines, Inc. · NasdaqGS

$314 +1.95% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 40 sessions
$400 $200 20 May 17 Jul

The line runs $336 on 20 May through $314 on 17 July, on a scale from $200 to $400. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of PRAX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 40 sessions over that window: $336 on 20 May 2026 through $314 on 17 July 2026.

Market cap $8.8B
52-week range $37.71 – $357
Avg volume 104.3K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

PRAX insider trades

SEC Form 4 · last 90 days · newest reported trade 24 Jun 2026
Open-market buys 0
Open-market sells 1
Net sold $3.61M
Non-trade filings 10
Date Insider Type Shares Value
24 Jun 2026 DeSimone Jill Director Sell 11,600 $3.61M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Jul 2026 Souza Marcio Chief Executive Officer Gift 23,121
24 Jun 2026 DeSimone Jill Director Option exercise 11,600 $826K
10 Jun 2026 Arbuckle Stuart A Director Award 1,371
10 Jun 2026 Chodakewitz Jeffrey Director Award 1,371
10 Jun 2026 Cudkowicz Merit Ester Director Award 1,371
10 Jun 2026 DeSimone Jill Director Award 1,371
10 Jun 2026 KINDLER JEFFREY B Director Award 1,371
10 Jun 2026 MITCHELL DEAN J Director Award 1,371
10 Jun 2026 Norden Gregory Director Award 1,371
10 Jun 2026 YOUNG WILLIAM D Director Award 1,371

PRAX reported financials

SEC EDGAR XBRL

PRAX reported revenue of $0 for the fiscal year ended 31 Dec 2025. Net income over the same period was −$303.3M.

Figure Reported Period
Revenue $0 31 Dec 2025 fiscal year
Net income −$303.3M 31 Dec 2025 fiscal year
Diluted EPS −$13.48 31 Dec 2025 fiscal year
Total assets $1.4B 30 Jun 2026 at period end
Total equity $1.3B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

PRAX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-2.87 —
31 Mar 2026 Q1 2026 $-3.20 —
31 Dec 2025 FY 2025 $-13.48 —
30 Sep 2025 Q3 2025 $-3.36 —
30 Jun 2025 Q2 2025 $-3.31 —
31 Mar 2025 Q1 2025 $-3.29 —
31 Dec 2024 FY 2024 $-10.21 $9M
30 Sep 2024 Q3 2024 $-2.75 $0M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

PRAX institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a PRAX position for the quarter ended 30 Jun 2026 — a combined $671.6M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 1,753,198 $587.0M
Marshall Wace Added +203.5% shares 137,008 $45.9M
AQR Capital Management Held (±25%) −0.4% shares 58,446 $19.6M
Man Group Added +567.0% shares 21,164 $7.1M
Two Sigma Investments Held (±25%) +6.6% shares 18,758 $6.3M
Citadel Advisors New position 7,331 $2.5M
D. E. Shaw & Co. New position 5,140 $1.7M
Tudor Investment Corp New position 2,183 $731K
Balyasny Asset Management New position 1,880 $629K
Millennium Management Trimmed −74.0% shares 995 $333K

Source: SEC EDGAR 13F filings

PRAX fails-to-deliver

SEC CNS data

On 08 Jul 2026, 8,350 shares of PRAX failed to deliver (about $2.7M).

Settlement date Shares failed Notional % of shares out
08 Jul 2026 8,350 $2.7M 0.030%
06 Jul 2026 568 $181K 0.002%

Source: SEC fails-to-deliver (CNS) data